UPDATE 1-AbbVie expects more than $3 billion in annual hep C drug sales
January 30, 2015 at 12:26 PM EST
Jan 30 (Reuters) - AbbVie Inc's chief executive said on Friday the company's new hepatitis C treatment Viekira Pak has the potential to capture a "meaningful share" of the U.S. market, where it is competing against Gilead Sciences .
